JP2023517295A - コロナウイルス感染の処置に使用する化合物 - Google Patents

コロナウイルス感染の処置に使用する化合物 Download PDF

Info

Publication number
JP2023517295A
JP2023517295A JP2022552932A JP2022552932A JP2023517295A JP 2023517295 A JP2023517295 A JP 2023517295A JP 2022552932 A JP2022552932 A JP 2022552932A JP 2022552932 A JP2022552932 A JP 2022552932A JP 2023517295 A JP2023517295 A JP 2023517295A
Authority
JP
Japan
Prior art keywords
day
compound
cov
substituted
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517295A5 (https=
Inventor
ホセ・マリア・フェルナンデス・ソウサ－ファロ
パブロ・アヴィレス・マリン
アレハンドロ・ロサーダ・ゴンザレス
サルヴァドール・フディオ・ムニョス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of JP2023517295A publication Critical patent/JP2023517295A/ja
Publication of JP2023517295A5 publication Critical patent/JP2023517295A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022552932A 2020-03-02 2021-03-02 コロナウイルス感染の処置に使用する化合物 Pending JP2023517295A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP20382152.5 2020-03-02
EP20382152 2020-03-02
EP20382192.1 2020-03-13
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382266.3 2020-04-02
EP20382339 2020-04-27
EP20382339.8 2020-04-27
EP20382816.5 2020-09-16
EP20382816 2020-09-16
EP20382815.7 2020-09-16
EP20382815 2020-09-16
PCT/EP2021/055137 WO2021175826A1 (en) 2020-03-02 2021-03-02 Compounds for use in the treatment of coronavirus infection

Publications (2)

Publication Number Publication Date
JP2023517295A true JP2023517295A (ja) 2023-04-25
JP2023517295A5 JP2023517295A5 (https=) 2024-03-12

Family

ID=74797953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552932A Pending JP2023517295A (ja) 2020-03-02 2021-03-02 コロナウイルス感染の処置に使用する化合物

Country Status (17)

Country Link
US (1) US20230158102A1 (https=)
EP (1) EP4114436A1 (https=)
JP (1) JP2023517295A (https=)
KR (1) KR20220151181A (https=)
CN (1) CN115666615A (https=)
AU (1) AU2021232534A1 (https=)
BR (1) BR112022017008A2 (https=)
CA (1) CA3169791A1 (https=)
CL (1) CL2022002398A1 (https=)
CO (1) CO2022014115A2 (https=)
IL (1) IL296066A (https=)
MX (1) MX2022010922A (https=)
PE (1) PE20231069A1 (https=)
PY (1) PY2117315A (https=)
TW (1) TW202144380A (https=)
UY (1) UY39108A (https=)
WO (1) WO2021175826A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021231521A1 (en) * 2020-03-02 2022-10-06 Pharma Mar, S.A. PLD for use in combination in the treatment of coronavirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517536A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 炎症状態に使用するための化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
JP2006523214A (ja) 2003-03-21 2006-10-12 ジユーリー，マデレーン・エム タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法
US7605135B2 (en) * 2003-11-10 2009-10-20 The University Of Hong Kong Baicalin as a treatment for SARS infection
JP2012512839A (ja) * 2008-12-19 2012-06-07 ファルマ、マール、ソシエダード、アノニマ 抗腫瘍性化合物
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517536A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 炎症状態に使用するための化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 112 (11): 3700, JPN6025002648, 2008, ISSN: 0005512724 *

Also Published As

Publication number Publication date
KR20220151181A (ko) 2022-11-14
UY39108A (es) 2021-09-30
CN115666615A (zh) 2023-01-31
PY2117315A (es) 2022-05-10
MX2022010922A (es) 2022-09-29
PE20231069A1 (es) 2023-07-17
AU2021232534A1 (en) 2022-10-06
TW202144380A (zh) 2021-12-01
US20230158102A1 (en) 2023-05-25
BR112022017008A2 (pt) 2022-10-11
CO2022014115A2 (es) 2022-11-18
IL296066A (en) 2022-11-01
CL2022002398A1 (es) 2023-06-30
EP4114436A1 (en) 2023-01-11
CA3169791A1 (en) 2021-09-10
WO2021175826A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
JP2023517536A (ja) 炎症状態に使用するための化合物
EP3952841A1 (en) Drug adsorbed highly porous activated carbon for enhanced drug delivery
JP2023520323A (ja) ２型アンギオテンシンｉｉ受容体アゴニストの新規使用
EP4138906A1 (en) Methods for the prophylaxis and treatment of covid and covid-19
JP2023517194A (ja) コロナウイルス感染の処置における組合せに使用するためのｐｌｄ
JP2023517295A (ja) コロナウイルス感染の処置に使用する化合物
Mina et al. Potential drug candidates underway several registered clinical trials for battling COVID-19
US20150165009A1 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
EA050340B1 (ru) Соединения для применения в лечении коронавирусной инфекции
US20240100025A1 (en) Materials and Methods for Treating Viral and Other Medical Conditions
Balef et al. A Recent Update on the Clinical Trials and Effectiveness of Drugs Used in COVID-19, MERS and SARS Coronaviruses
EA050436B1 (ru) Соединения для применения при воспалительных состояниях
WO2023192779A2 (en) Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections
JP2023517537A (ja) 自己免疫状態に使用するための化合物
Aoki Peramivir

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20221201

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20220902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250715